In order for the immune system to effectively attack foreign cells, it relies on “checkpoints”—molecules on certain immune cells that activate (or inactivate) before initiating a response. Attend this session to hear experts in the field briefly review the immunology and pathways targeted by immune checkpoint inhibitors. They’ll also dive deep into related complications and present opportunities for community pharmacists to optimize care for patients receiving checkpoint inhibitor–based cancer therapy.
This activity is supported by an independent educational grant from Merck Sharp and Dohme Corp.
At the completion of this application-based activity, participants will be able to
- State the mechanism of action of immune checkpoint inhibitors.
- Describe common symptoms associated with the use of immune checkpoint inhibitors.
- Discuss the appropriate steps a community pharmacist can take when encountering a patient receiving checkpoint inhibitor–based therapy who is exhibiting symptoms consistent with therapy complications.
Activity type: Application-based
Target Audience: Pharmacists
Learning Level: 2
The American Pharmacists Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The following archived webinar is approved for 1.5 contact hours of CPE credit (0.15 CEUs). The ACPE Universal Activity Number for this activity is 0202-0000-20-041-H01-P.
To obtain credit for completing Inhibitor-Based Cancer Therapy: How Community Pharmacists Can Optimize Care, participants will need to watch the archived webinar, complete the assessment with a grade of 70% or better, complete the evaluation questions, and then CLAIM credit. Participants need to have a valid pharmacist.com username and password to claim credit. After credit has been claimed, please visit CPE monitor for your transcript.
APhA continuing pharmacy education policy provides you with two opportunities to successfully complete this continuing pharmacy education assessment. Please note that you will not be permitted to submit the assessment a third time. The current policy of the APhA Education Department is not to release the correct answers to any of our CPE tests. This policy is intended to maintain the integrity of the CPE activity and the assessment.Initial release date: March 23, 2020
Expiration date: March 22, 2023 - No credit granted after this date
Development and Support
Inhibitor-Based Cancer Therapy: How Community Pharmacists Can Optimize Care is an activity for pharmacists developed by the American Pharmacists Association. This activity is supported by an independent educational grant from Merck Sharp and Dohme Corp. © 2020 American Pharmacists Association
Daniel Zlott, PharmD, BCOP; Tricia Schneider, PharmD, MBA; and APhA’s editorial staff declare no conflicts of interest or financial interests in any product or service mentioned in this activity, including grants, employment, gifts, stock holdings, and honoraria. For a complete list of APhA staff disclosures, visit the APhA website at www.pharmacist.com/apha-disclosures.
Conflicts of interest have been resolved through content review by Helen Sairany, BA, PharmD, MBA, BCACP, Director of Content Development & Partnership at the American Pharmacists Association.
This learning product is a component of the APhA2020 Virtual Education package.
Computer and internet access are required to complete this activity. Please visit our website to view the Technology System Requirements in order to have a positive learning experience.
|Activity Number||Credit Amount||Accreditation Period|
|ACPE# 0202-0000-20-041-H01-P||0.15 CEUs||March 20, 2020 - March 20, 2023|